Literature DB >> 21731885

Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.

Ebru Demirel Sezer1, Eser Yildirim Sozmen, Deniz Nart, Taner Onat.   

Abstract

BACKGROUND: The aim of this study was to determine the oxidant-antioxidant status and lipid peroxidation products, as well as paraoxonase and atherosclerotic plaque formation, in a hypercholesterolemic atherosclerosis rabbit model to investigate the effects of atorvastatin in the atherosclerotic process.
METHODS: Forty male New Zealand rabbits were divided into four groups, ie, a control group receiving standard pellets, a group receiving atorvastatin therapy, a hypercholesterolemic group receiving an atherogenic diet, and a group receiving both an atherogenic diet and atorvastatin.
RESULTS: The atherogenic diet increased the levels of low-density lipoprotein (LDL) thiobarbituric acid reactive substances (1.84 vs 3.79 nmol/mg protein) and LDL-conjugated diene (147 vs 318 μmol/mg protein) after induction of oxidation by Cu(2+), despite an increase of superoxide dismutase activity. Treatment with atorvastatin limited LDL oxidation significantly (LDL thiobarbituric acid reactive substances 2.19 nmol/mg protein, LDL-conjugated diene 222 μmol/mg protein). Paraoxonase, which prevents LDL oxidation and inactivates LDL-derived oxidized phospholipids, showed a pronounced decrease in the group receiving the atherogenic diet (110 U/L to 28 U/L), and atorvastatin treatment increased paraoxonase activity. Histological examination of arcus aorta tissues from the hypercholesterolemic group showed abundant plaque formation surrounding and obstructing the lumen, whereas treatment with atorvastatin prevented or limited plaque formation, keeping the plaque thin and localized.
CONCLUSION: Atorvastatin has dramatic antiatherosclerotic effects, part of which seems to be due to the antioxidant features of the parent drug and/or its metabolites, favoring inhibition of LDL oxidation.

Entities:  

Keywords:  atherosclerosis; atorvastatin; hypercholesterolemia; low-density lipoprotein oxidation; paraoxonase

Mesh:

Substances:

Year:  2011        PMID: 21731885      PMCID: PMC3119591          DOI: 10.2147/VHRM.S17781

Source DB:  PubMed          Journal:  Vasc Health Risk Manag        ISSN: 1176-6344


  43 in total

Review 1.  Atherosclerosis is an inflammatory disease.

Authors:  R Ross
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

2.  The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.

Authors:  Cihan Orem; Asim Orem; Hüseyin Avni Uydu; Sükrü Celik; Cevdet Erdöl; Birgül Vanizor Kural
Journal:  Coron Artery Dis       Date:  2002-02       Impact factor: 1.439

3.  Antioxidant enzymes and paraoxonase show a co-activity in preserving low-density lipoprotein from oxidation.

Authors:  E Y Sözmen; B Sözmen; F K Girgin; Y Delen; E Azarsiz; D Erdener; B Ersöz
Journal:  Clin Exp Med       Date:  2001-12       Impact factor: 3.984

Review 4.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans?

Authors:  J L Witztum; D Steinberg
Journal:  Trends Cardiovasc Med       Date:  2001 Apr-May       Impact factor: 6.677

5.  Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?

Authors:  B Mackness; G K Davies; W Turkie; E Lee; D H Roberts; E Hill; C Roberts; P N Durrington; M I Mackness
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-09       Impact factor: 8.311

6.  Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Margaret Springett; Thomas C Sebo; Marek Niekrasz; Joseph P McConnell; Ravinder J Singh; Neil J Stone; Robert O Bonow; Thomas C Spelsberg
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

7.  Cellular antioxidant effects of atorvastatin in vitro and in vivo.

Authors:  Sven Wassmann; Ulrich Laufs; Kirsten Müller; Christian Konkol; Katja Ahlbory; Anselm T Bäumer; Wolfgang Linz; Michael Böhm; Georg Nickenig
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-02-01       Impact factor: 8.311

8.  Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy.

Authors:  Massimo Puato; Elisabetta Faggin; Marcello Rattazzi; Alberto Zambon; Francesco Cipollone; Franco Grego; Lorenzo Ganassin; Mario Plebani; Andrea Mezzetti; Paolo Pauletto
Journal:  Stroke       Date:  2010-04-22       Impact factor: 7.914

Review 9.  Extracellular superoxide dismutase and cardiovascular disease.

Authors:  Tohru Fukai; Rodney J Folz; Ulf Landmesser; David G Harrison
Journal:  Cardiovasc Res       Date:  2002-08-01       Impact factor: 10.787

10.  Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.

Authors:  Bianca Fuhrman; Lena Koren; Nina Volkova; Shlomo Keidar; Tony Hayek; Michael Aviram
Journal:  Atherosclerosis       Date:  2002-09       Impact factor: 5.162

View more
  11 in total

1.  Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.

Authors:  Thiago Santos Ferreira; Manuella Lanzetti; Marina Valente Barroso; Carlos Romualdo Rueff-Barroso; Cláudia Farias Benjamim; Lycia de Brito-Gitirana; Luís Cristóvão Porto; Samuel Santos Valença
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

2.  Antioxidant and anti-inflammatory effects of Marrubium alysson extracts in high cholesterol-fed rabbits.

Authors:  Soha S Essawy; Dina M Abo-Elmatty; Nabila M Ghazy; Jihan M Badr; Olov Sterner
Journal:  Saudi Pharm J       Date:  2013-12-21       Impact factor: 4.330

3.  The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.

Authors:  Leo R Zacharski; Ralph G DePalma; Galina Shamayeva; Bruce K Chow
Journal:  Am J Public Health       Date:  2013-02-14       Impact factor: 9.308

4.  Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis.

Authors:  Puneet Dhamija; Debasish Hota; Rakesh Kochhar; Atul Sachdev; Amitava Chakrabarti
Journal:  Indian J Gastroenterol       Date:  2013-11-13

Review 5.  Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.

Authors:  Marios Margaritis; Keith M Channon; Charalambos Antoniades
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

6.  Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice.

Authors:  Li-Yan Zhao; Jie Li; Feng Yuan; Mei Li; Quan Zhang; Yun-Ying Huang; Ji-Yan Pang; Bin Zhang; Fang-Yun Sun; Hong-Shuo Sun; Qian Li; Lu Cao; Yu Xie; Yong-Cheng Lin; Jie Liu; Hong-Mei Tan; Guan-Lei Wang
Journal:  Mar Drugs       Date:  2015-04-14       Impact factor: 5.118

7.  15-Lipoxygenase-1 Is Involved in the Effects of Atorvastatin on Endothelial Dysfunction.

Authors:  Peng Zhang; Xin Xing; Chunxiao Hu; Hui Yu; Qian Dong; Guanglei Chang; Shu Qin; Jian Liu; Dongying Zhang
Journal:  Mediators Inflamm       Date:  2016-08-10       Impact factor: 4.711

8.  Increased Serum Lipid Levels in Patients with Subjective Tinnitus.

Authors:  Deniz Avcı
Journal:  Iran J Otorhinolaryngol       Date:  2021-01

9.  Astaxanthin prevents changes in the activities of thioredoxin reductase and paraoxonase in hypercholesterolemic rabbits.

Authors:  Paula R Augusti; Andréia Quatrin; Sabrina Somacal; Greicy Mm Conterato; Rocheli Sobieski; Amanda R Ruviaro; Luana H Maurer; Marta Mf Duarte; Miguel Roehrs; Tatiana Emanuelli
Journal:  J Clin Biochem Nutr       Date:  2012-06-08       Impact factor: 3.114

Review 10.  Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis.

Authors:  Joselyn Rojas; Juan Salazar; María Sofía Martínez; Jim Palmar; Jordan Bautista; Mervin Chávez-Castillo; Alexis Gómez; Valmore Bermúdez
Journal:  Scientifica (Cairo)       Date:  2015-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.